viewShield Therapeutics PLC

Shield Therapeutics' on cusp of US market expansion with focus on commercialising Accrufer

Shield Therapeutics PLC (LSE:STX, FRA:1JS)'s (LON:STX, OTCQX:SHIEF) investment case is presented by Proactive Research Analyst John Savin who explains how the firm hinges on the success of their US launch of commercialising Accrufer.

This treatment is for iron deficiency or anaemia and as Savin explains Shield owns the product, which means they would be taking all the profit but, most importantly, controlling the process.

He says the market is large with 10mln oral prescriptions a year. And Accrufer offers excellent tolerability and efficacy compared to other oral iron products.

Click here to read Proactive analysts' Robin Davison & John Savin's latest research update on 'Shield Therapeutics: Master of its own destiny'

Quick facts: Shield Therapeutics PLC


Price: 42 GBX

Market Cap: £90.67 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...


Shield Therapeutics: Analysis of data from AEGIS-H2H is strongly supportive...

Proactive Research analyst Emma Ulker says further conclusions from Shield Therapeutics' (LON:STX) analysis of data from the AEGIS-H2H study are strongly supportive of ongoing discussions for the global commercialisation, pricing and reimbursement of Feraccru. She adds that with the analysis...

on 08/10/2020

2 min read